Literature DB >> 20510264

Management of herpes zoster and post-herpetic neuralgia now and in the future.

Richard J Whitley1, Antonio Volpi, Mike McKendrick, Albert van Wijck, Anne Louise Oaklander.   

Abstract

Herpes zoster (HZ; shingles)--a reactivation of the latent varicella zoster virus (VZV)--can cause significant morbidity. Its major complication is pain, particularly post-herpetic neuralgia (PHN). We will review the current management strategies available for the treatment of both acute HZ and PHN, including antiviral drugs, analgesic agents, anticonvulsants, tricyclic antidepressants and topical therapies. New molecules in development that show improved activity against VZV are also covered, and new drug targets are outlined. The role of translational neuroscience in moving towards a goal of finding disease-modifying treatments will be examined. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510264     DOI: 10.1016/S1386-6532(10)70005-6

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  25 in total

1.  Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.

Authors:  Michael N Oxman; Ruth Harbecke; David M Koelle
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

2.  Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection.

Authors:  Wen-Bo Zeng; Fukun Zhang; Shuang Cheng; Jin-Yan Sun; Hongjie Shen; Min-Hua Luo
Journal:  Virol Sin       Date:  2020-05-28       Impact factor: 4.327

4.  Acute Glaucoma Filtering Surgery Failure following Herpes Zoster Ophthalmicus Infection.

Authors:  Stylianos A Kandarakis; Andreas Diagourtas; Petros Petrou; Filippos Vingopoulos; Konstantinos Droutsas; Evangelia Papakonstantinou; Iias Georgalas
Journal:  Case Rep Ophthalmol       Date:  2021-05-03

Review 5.  Prevention strategies for herpes zoster and post-herpetic neuralgia.

Authors:  Myron J Levin; Anne A Gershon; Robert H Dworkin; Marc Brisson; Lawrence Stanberry
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

Review 6.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

7.  Bee venom treatment for refractory postherpetic neuralgia: a case report.

Authors:  Seung Min Lee; Jinwoong Lim; Jae-Dong Lee; Do-Young Choi; Sanghoon Lee
Journal:  J Altern Complement Med       Date:  2013-10-05       Impact factor: 2.579

8.  Association between herpes zoster and end stage renal disease entrance in chronic kidney disease patients: a population-based cohort study.

Authors:  S-Y Lin; J-H Liu; H-C Yeh; C-L Lin; I-J Tsai; P-C Chen; F-C Sung; Y-F Yang; C-C Huang; D E Morisky; Y-J Chang; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-17       Impact factor: 3.267

9.  Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy.

Authors:  Giustino Parruti; Monica Tontodonati; Cristina Rebuzzi; Ennio Polilli; Federica Sozio; Augusta Consorte; Adriana Agostinone; Francesco Di Masi; Gabriele Congedo; Domenico D'Antonio; Carla Granchelli; Claudio D'Amario; Carlo Carunchio; Lucio Pippa; Lamberto Manzoli; Antonio Volpi
Journal:  BMC Med       Date:  2010-10-11       Impact factor: 8.775

Review 10.  Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.

Authors:  Marta López-Fauqued; Maribel Co-van der Mee; Adriana Bastidas; Pierre Beukelaers; Alemnew F Dagnew; Juan Jose Fernandez Garcia; Anne Schuind; Fernanda Tavares-da-Silva
Journal:  Drug Saf       Date:  2021-06-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.